Borean Pharma receives Notice of Allowance of HIV drug patent by U.S. Patent & Trademark Office

25-Oct-2007 - Borean Pharma, ApS announced that it has received a Notice of Allowance from the U.S. Patent & Trademark Office (USPTO) in connection with Borean's patent application for Human Immunodeficiency Virus (HIV) fusion inhibitors for treating AIDS. The USPTO has stated that it intends to grant patent ...

Eden Biodesign and Borean Pharma ApS sign deal to develop novel therapeutic candidate for the treatment of cancer

12-Sep-2007 - Eden Biodesign Ltd and Borean Pharma ApS announced that they have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies. The project is expected to complete early in ...

Borean Pharma Granted United States Patent

Lead Therapeutic Candidate for Atherosclerosis

02-Jun-2005 - Borean Pharma A/S, the biopharmaceutical and protein engineering company, announced that the U.S. Patent and Trademark Office has issued a U.S. Patent (No. 6,897,039) for the Company's atherosclerosis drug candidate, Trimeric Apolipoprotein A-I, which is in preclinical development. The Borean ...

Borean Pharma Acquires Proteopharma and Promising Arterial Drug

20-Feb-2004 - Aarhus, Demark. Borean Pharma A/S announced that it has acquired the Aarhus based biotech company Proteopharma, which holds patents for a protein that may reduce arterial cholesterol plaque and prevent blood clots, one of the Western world's leading causes of death. Deal terms were not ...